Juluca - A Two-Drug Complete Regimen for HIV (online only)
Juluca - A Two-Drug Complete Regimen for HIV (online only)
December 3, 2018 (Issue: 1561)
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase
strand transfer inhibitor (INSTI) dolutegravir (Tivicay)
and the non-nucleoside reverse transcriptase
inhibitor (NNRTI) rilpivirine (Edurant), as a...more
- Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: aidsinfo.nih.gov. Accessed November 26, 2018.
- JM Libre et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391:839.
- GA McComsey et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS 2018; 32:477.
- FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). Available at: www.fda.gov. Accessed November 26, 2018.
- O Osiyemi et al. Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a phase 3b, multicenter, open-label study. Infect Dis Ther 2018; 7:147.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RL Woosley and KA Romero. QT drugs list. Available at: www.crediblemeds.org. Accessed November 26, 2018.
- Drugs for HIV infection. Treat Guidel Med Lett 2014; 12:7.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Juluca - A Two-Drug Complete Regimen for HIV (online only)
Article code: 1561g
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.